HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights
10 nov. 2021 06h30 HE
|
HOOKIPA Pharma Inc.
Clinical collaboration with Merck & Co., Inc., Kenilworth, NJ, USA, set to evaluate HB-201 in combination with pembrolizumab in 1st- and 2nd-line HNSCC patientsBased on recent strong data updates,...
HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on clinical data updates across its novel arenaviral platform
09 nov. 2021 16h01 HE
|
HOOKIPA Pharma Inc.
Based on positive interim Phase 1 data, HOOKIPA initiates Phase 2 study to assess HB-201 in combination with pembrolizumab in 1st and 2nd line head and neck cancerInterim Phase 1 HB-200 data continue...
HOOKIPA Pharma to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
03 nov. 2021 08h18 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA announces publication on the benefits of its novel arenaviral immunotherapeutics in cancer in Frontiers in Oncology
14 oct. 2021 07h00 HE
|
HOOKIPA Pharma Inc.
Comprehensive review highlights potential of HOOKIPA’s versatile arenavirus platform as a new immunotherapy strategy to address critical unmet needs in cancerPre-clinical and clinical data showcase...
HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancers
15 sept. 2021 07h00 HE
|
HOOKIPA Pharma Inc.
Clinical collaboration to assess HB-200 in combination with KEYTRUDA® (pembrolizumab) as first-line treatmentHOOKIPA poised to advance clinical development program with randomized Phase 2 study in...
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
07 sept. 2021 10h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma Reports Second Quarter 2021 Financial Results and Recent Highlights
12 août 2021 07h00 HE
|
HOOKIPA Pharma Inc.
Phase 1 HB-200 data recognized at premier oncology meetings, highlighting potential of novel arenaviral platform to deliver a new class of immunotherapeuticsHOOKIPA on track to report comprehensive...
Pre-clinical data on HOOKIPA’s arenaviral immunotherapeutic in melanoma published in Nature Communications
05 août 2021 05h30 HE
|
HOOKIPA Pharma Inc.
HOOKIPA’s arenaviral platform technology demonstrated ability to modulate the tumor microenvironment and induce potent melanoma-specific T cell responsesA single, intra-tumoral injection of the...
HOOKIPA Pharma to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021
03 août 2021 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Aug. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in June
10 juin 2021 07h30 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, June 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...